Open Access
Open access
Interdisciplinary Perspectives on Infectious Diseases, volume 2012, pages 1-37

Global Fluoroquinolone Resistance Epidemiology and Implictions for Clinical Use

Dalhoff Axel 1
1
 
Institute for Infection-Medicine, Christian-Albrechts Univerity of Kiel and University Medical Center Schleswig-Holstein, Brunswiker Straße 4, 24105 Kiel, Germany
Publication typeJournal Article
Publication date2012-10-25
Quartile SCImago
Q2
Quartile WOS
Impact factor
ISSN1687708X, 16877098
PubMed ID:  23097666
Microbiology (medical)
Microbiology
Infectious Diseases
Parasitology
Virology
Abstract
This paper on the fluoroquinolone resistance epidemiology stratifies the data according to the different prescription patterns by either primary or tertiary caregivers and by indication. Global surveillance studies demonstrate that fluoroquinolone resistance rates increased in the past years in almost all bacterial species except S. pneumoniae and H. influenzae, causing community-acquired respiratory tract infections. However, 10 to 30% of these isolates harbored first-step mutations conferring low level fluoroquinolone resistance. Fluoroquinolone resistance increased in Enterobacteriaceae causing community acquired or healthcare associated urinary tract infections and intraabdominal infections, exceeding 50% in some parts of the world, particularly in Asia. One to two-thirds of Enterobacteriaceae producing extended spectrum β-lactamases were fluoroquinolone resistant too. Furthermore, fluoroquinolones select for methicillin resistance in Staphylococci. Neisseria gonorrhoeae acquired fluoroquinolone resistance rapidly; actual resistance rates are highly variable and can be as high as almost 100%, particularly in Asia, whereas resistance rates in Europe and North America range from <10% in rural areas to >30% in established sexual networks. In general, the continued increase in fluoroquinolone resistance affects patient management and necessitates changes in some guidelines, for example, treatment of urinary tract, intra-abdominal, skin and skin structure infections, and traveller's diarrhea, or even precludes the use in indications like sexually transmitted diseases and enteric fever.

Citations by journals

1
2
3
4
5
6
7
8
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy, 8, 3.79%
Antimicrobial Agents and Chemotherapy
8 publications, 3.79%
Antibiotics
Antibiotics, 8, 3.79%
Antibiotics
8 publications, 3.79%
Frontiers in Microbiology
Frontiers in Microbiology, 8, 3.79%
Frontiers in Microbiology
8 publications, 3.79%
Microbial Drug Resistance
Microbial Drug Resistance, 7, 3.32%
Microbial Drug Resistance
7 publications, 3.32%
Scientific Reports
Scientific Reports, 4, 1.9%
Scientific Reports
4 publications, 1.9%
Infection Control and Hospital Epidemiology
Infection Control and Hospital Epidemiology, 4, 1.9%
Infection Control and Hospital Epidemiology
4 publications, 1.9%
Canadian Journal of Microbiology
Canadian Journal of Microbiology, 3, 1.42%
Canadian Journal of Microbiology
3 publications, 1.42%
Journal of Medical Microbiology
Journal of Medical Microbiology, 3, 1.42%
Journal of Medical Microbiology
3 publications, 1.42%
Pathogens
Pathogens, 3, 1.42%
Pathogens
3 publications, 1.42%
BMC Infectious Diseases
BMC Infectious Diseases, 3, 1.42%
BMC Infectious Diseases
3 publications, 1.42%
Expert Opinion on Pharmacotherapy
Expert Opinion on Pharmacotherapy, 3, 1.42%
Expert Opinion on Pharmacotherapy
3 publications, 1.42%
Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, 3, 1.42%
Journal of Antimicrobial Chemotherapy
3 publications, 1.42%
Wellcome Open Research
Wellcome Open Research, 2, 0.95%
Wellcome Open Research
2 publications, 0.95%
Otology and Neurotology
Otology and Neurotology, 2, 0.95%
Otology and Neurotology
2 publications, 0.95%
Molecules
Molecules, 2, 0.95%
Molecules
2 publications, 0.95%
Microorganisms
Microorganisms, 2, 0.95%
Microorganisms
2 publications, 0.95%
Pharmaceutics
Pharmaceutics, 2, 0.95%
Pharmaceutics
2 publications, 0.95%
BMC Microbiology
BMC Microbiology, 2, 0.95%
BMC Microbiology
2 publications, 0.95%
BMC Genomics
BMC Genomics, 2, 0.95%
BMC Genomics
2 publications, 0.95%
Bioorganic and Medicinal Chemistry Letters
Bioorganic and Medicinal Chemistry Letters, 2, 0.95%
Bioorganic and Medicinal Chemistry Letters
2 publications, 0.95%
International Journal of Antimicrobial Agents
International Journal of Antimicrobial Agents, 2, 0.95%
International Journal of Antimicrobial Agents
2 publications, 0.95%
Journal of Global Antimicrobial Resistance
Journal of Global Antimicrobial Resistance, 2, 0.95%
Journal of Global Antimicrobial Resistance
2 publications, 0.95%
ACS Infectious Diseases
ACS Infectious Diseases, 2, 0.95%
ACS Infectious Diseases
2 publications, 0.95%
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry, 2, 0.95%
Journal of Medicinal Chemistry
2 publications, 0.95%
MedChemComm
MedChemComm, 2, 0.95%
MedChemComm
2 publications, 0.95%
Xenobiotica
Xenobiotica, 2, 0.95%
Xenobiotica
2 publications, 0.95%
Clinical Microbiology Reviews
Clinical Microbiology Reviews, 2, 0.95%
Clinical Microbiology Reviews
2 publications, 0.95%
Biomedicines
Biomedicines, 2, 0.95%
Biomedicines
2 publications, 0.95%
Current Computer-Aided Drug Design
Current Computer-Aided Drug Design, 1, 0.47%
Current Computer-Aided Drug Design
1 publication, 0.47%
1
2
3
4
5
6
7
8

Citations by publishers

5
10
15
20
25
30
35
Springer Nature
Springer Nature, 34, 16.11%
Springer Nature
34 publications, 16.11%
Elsevier
Elsevier, 30, 14.22%
Elsevier
30 publications, 14.22%
Multidisciplinary Digital Publishing Institute (MDPI)
Multidisciplinary Digital Publishing Institute (MDPI), 23, 10.9%
Multidisciplinary Digital Publishing Institute (MDPI)
23 publications, 10.9%
Taylor & Francis
Taylor & Francis, 14, 6.64%
Taylor & Francis
14 publications, 6.64%
American Society for Microbiology
American Society for Microbiology, 12, 5.69%
American Society for Microbiology
12 publications, 5.69%
Frontiers Media S.A.
Frontiers Media S.A., 11, 5.21%
Frontiers Media S.A.
11 publications, 5.21%
Mary Ann Liebert
Mary Ann Liebert, 9, 4.27%
Mary Ann Liebert
9 publications, 4.27%
Oxford University Press
Oxford University Press, 9, 4.27%
Oxford University Press
9 publications, 4.27%
American Chemical Society (ACS)
American Chemical Society (ACS), 5, 2.37%
American Chemical Society (ACS)
5 publications, 2.37%
Cambridge University Press
Cambridge University Press, 4, 1.9%
Cambridge University Press
4 publications, 1.9%
BMJ
BMJ, 4, 1.9%
BMJ
4 publications, 1.9%
Canadian Science Publishing
Canadian Science Publishing, 3, 1.42%
Canadian Science Publishing
3 publications, 1.42%
Future Medicine
Future Medicine, 3, 1.42%
Future Medicine
3 publications, 1.42%
Microbiology Society
Microbiology Society, 3, 1.42%
Microbiology Society
3 publications, 1.42%
Wolters Kluwer Health
Wolters Kluwer Health, 3, 1.42%
Wolters Kluwer Health
3 publications, 1.42%
Wiley
Wiley, 3, 1.42%
Wiley
3 publications, 1.42%
Bentham Science
Bentham Science, 2, 0.95%
Bentham Science
2 publications, 0.95%
Pharmaceutical Society of Japan
Pharmaceutical Society of Japan, 2, 0.95%
Pharmaceutical Society of Japan
2 publications, 0.95%
Royal Society of Chemistry (RSC)
Royal Society of Chemistry (RSC), 2, 0.95%
Royal Society of Chemistry (RSC)
2 publications, 0.95%
Hindawi Limited
Hindawi Limited, 2, 0.95%
Hindawi Limited
2 publications, 0.95%
Centers for Disease Control and Prevention (CDC)
Centers for Disease Control and Prevention (CDC), 1, 0.47%
Centers for Disease Control and Prevention (CDC)
1 publication, 0.47%
PeerJ
PeerJ, 1, 0.47%
PeerJ
1 publication, 0.47%
Spandidos Publications
Spandidos Publications, 1, 0.47%
Spandidos Publications
1 publication, 0.47%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii, 1, 0.47%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.47%
Public Library of Science (PLoS)
Public Library of Science (PLoS), 1, 0.47%
Public Library of Science (PLoS)
1 publication, 0.47%
British Veterinary Association
British Veterinary Association, 1, 0.47%
British Veterinary Association
1 publication, 0.47%
Korea Centers for Disease Control and Prevention, 1, 0.47%
Korea Centers for Disease Control and Prevention
1 publication, 0.47%
Brazilian Society of Urology, 1, 0.47%
Brazilian Society of Urology
1 publication, 0.47%
Lavoisier, 1, 0.47%
Lavoisier
1 publication, 0.47%
5
10
15
20
25
30
35
  • We do not take into account publications that without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Dalhoff A. Global Fluoroquinolone Resistance Epidemiology and Implictions for Clinical Use // Interdisciplinary Perspectives on Infectious Diseases. 2012. Vol. 2012. pp. 1-37.
GOST all authors (up to 50) Copy
Dalhoff A. Global Fluoroquinolone Resistance Epidemiology and Implictions for Clinical Use // Interdisciplinary Perspectives on Infectious Diseases. 2012. Vol. 2012. pp. 1-37.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1155/2012/976273
UR - https://doi.org/10.1155%2F2012%2F976273
TI - Global Fluoroquinolone Resistance Epidemiology and Implictions for Clinical Use
T2 - Interdisciplinary Perspectives on Infectious Diseases
AU - Dalhoff, Axel
PY - 2012
DA - 2012/10/25 00:00:00
PB - Hindawi Limited
SP - 1-37
VL - 2012
PMID - 23097666
SN - 1687-708X
SN - 1687-7098
ER -
BibTex
Cite this
BibTex Copy
@article{2012_Dalhoff,
author = {Axel Dalhoff},
title = {Global Fluoroquinolone Resistance Epidemiology and Implictions for Clinical Use},
journal = {Interdisciplinary Perspectives on Infectious Diseases},
year = {2012},
volume = {2012},
publisher = {Hindawi Limited},
month = {oct},
url = {https://doi.org/10.1155%2F2012%2F976273},
pages = {1--37},
doi = {10.1155/2012/976273}
}
Found error?